Publications by authors named "Raynier Devillier"

60Publications

Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy.

J Leukoc Biol 2020 Sep 29. Epub 2020 Sep 29.

Immunity and Cancer Team, Paoli-Calmettes Institute, Aix-Marseille University, CNRS, INSERM, CRCM, Marseille, France.

View Article and Find Full Text PDF
September 2020

[PD-L1 glycosylation under the spotlights].

Med Sci (Paris) 2020 Jun-Jul;36(6-7):552-555. Epub 2020 Jul 2.

Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm UMR1068, CNRS UMR7258, Institut Paoli Calmettes, 27 boulevard Leï Roure, CS 30059, 13273 Marseille Cedex 09, France.

View Article and Find Full Text PDF
November 2020

[Haploidentical hematopoietic stem cell transplant: How to choose the best donor? Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Bull Cancer 2020 Jan 2;107(1S):S72-S84. Epub 2019 Oct 2.

Université Paris 6 Pierre-et-Marie-Curie, groupe hospitalier Pitié-Salpêtrière, centre d'immunologie et des maladies infectieuses (CIMI-Paris), service d'hématologie clinique, UPMC CR7, CNRS ERL8255, Inserm U1135, 75013 Paris, France. Electronic address:

View Article and Find Full Text PDF
January 2020

Clinical outcome of FLAG-IDA chemotherapy sequential with Flu-Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes.

Bone Marrow Transplant 2019 03 6;54(3):458-464. Epub 2018 Aug 6.

Shanghai Institute of Hematology, Department of Hematology, Blood and Marrow Transplantation Center, Collaborative Innovation Center of Hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 18F/OPD Bldg 197 Rui Jin Road II, 200025, Shanghai, China.

View Article and Find Full Text PDF
March 2019

Killer Cell Immunoglobulin-Like Receptor-Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell-Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide.

Biol Blood Marrow Transplant 2018 03 13;24(3):549-554. Epub 2017 Dec 13.

Department of Hematology, Institut Paoli-Calmettes, Marseille, France; Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR 7258, Marseille, France; Medical Faculty, Aix-Marseille University, UM 105, Marseille, France. Electronic address:

View Article and Find Full Text PDF
March 2018

T-cell-replete haploidentical transplantation in acute myeloid leukemia.

Exp Hematol 2018 02 17;58:5-16. Epub 2017 Nov 17.

Department of Hematology, Institut Paoli-Calmettes, Marseille, France; Aix-Marseille University UM 105, Marseille, France; Centre de Recherche en Cancérologie de Marseille, Inserm, U1068, CNRS UMR 7258, Marseille, France. Electronic address:

View Article and Find Full Text PDF
February 2018

Immune checkpoints inhibitors for solid tumours after allogeneic haematopoietic stem-cell transplantation: About four clinical cases.

Eur J Cancer 2017 08;81:138-141

Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France; Aix Marseille Univ, CNRS U7258, INSERM U1068, Institut Paoli-Calmettes, CRCM, Marseille, France. Electronic address:

View Article and Find Full Text PDF
August 2017

Manufacturing Natural Killer Cells as Medicinal Products.

Front Immunol 2016 15;7:504. Epub 2016 Nov 15.

CBT-1409: INSERM, Aix Marseille Univ, Institut Paoli-Calmettes, AP-HM, Marseille, France; CRCM: INSERM, CNRS, Aix Marseille Univ, Institut Paoli-Calmettes, CRCM, Marseille, France.

View Article and Find Full Text PDF
November 2016

Epigenetically centered evolution in an example of myeloid malignancy.

Am J Hematol 2016 09 4;91(9):E361-2. Epub 2016 Jul 4.

Centre de Recherche en Cancérologie de Marseille, Laboratoire D'Oncologie Moléculaire, UMR1068 Inserm, Institut Paoli-Calmettes, CNRS UMR725, Marseille, France.

View Article and Find Full Text PDF
September 2016

Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial.

Haematologica 2015 Feb 25;100(2):269-74. Epub 2014 Nov 25.

Hematology Department, University Hospital Center, Nantes CRNCA, UMR 892 INSERM - 6299 CNRS, and Université de Nantes, Faculté de Médecine, Nantes, France Hematology and Cellular Therapy Unit, AP-HP, Université Paris 6, Hôpital Saint Antoine, Paris, France.

View Article and Find Full Text PDF
February 2015

Constitutive AKT activation in follicular lymphoma.

BMC Cancer 2014 Aug 5;14:565. Epub 2014 Aug 5.

Inserm, U1068, Centre de Recherche en Cancérologie de Marseille, Marseille, France.

View Article and Find Full Text PDF
August 2014

Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies.

Haematologica 2014 Nov 1;99(11):1762-8. Epub 2014 Aug 1.

Département d'Hématologie, Institut Paoli Calmettes, Marseille, France Aix-Marseille University, Marseille, France Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France

View Article and Find Full Text PDF
November 2014

Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.

Biol Blood Marrow Transplant 2014 Oct 14;20(10):1560-5. Epub 2014 Jun 14.

Hematology Department, Transplantation Program, Institut Paoli Calmettes, Marseille, France; Aix-Marseille Université, Marseille, France; Inserm UMR 1068/Centre de Recherche en Cancérologie de Marseille, Marseille, France.

View Article and Find Full Text PDF
October 2014

Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.

Biol Blood Marrow Transplant 2014 Mar 4;20(3):370-4. Epub 2013 Dec 4.

Hematology Department, Transplantation Program, Institut Paoli Calmettes, Marseille, France; Aix-Marseille Université, Marseille, France; Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France. Electronic address:

View Article and Find Full Text PDF
March 2014

A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.

Am J Hematol 2014 Jan;89(1):83-7

Département d'Onco-Hématologie, Institut Paoli-Calmettes, Unité de Transplantation et de Thérapie Cellulaire, F-13273, Marseille, France; Aix-Marseille Université, F-13007, Marseille, France; Inserm UMR1068, Centre de Recherche en Cancérologie de Marseille (CRCM), F-13009, Marseille, France.

View Article and Find Full Text PDF
January 2014

Myeloid malignancies: mutations, models and management.

BMC Cancer 2012 Jul 23;12:304. Epub 2012 Jul 23.

Centre de Recherche en Cancérologie de Marseille, Laboratoire d'Oncologie Moléculaire; UMR1068 Inserm, Institut Paoli-Calmettes, 27 Bd, Leï Roure, BP 30059, Marseille, 13273, France.

View Article and Find Full Text PDF
July 2012

Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.

Am J Hematol 2012 Jul 25;87(7):659-62. Epub 2012 Apr 25.

Centre de Recherche en Cancérologie de Marseille, Laboratoire d'Oncologie Moléculaire, UMR Inserm, Institut Paoli-Calmettes, Marseille, France.

View Article and Find Full Text PDF
July 2012

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

J Hematol Oncol 2012 Mar 21;5:12. Epub 2012 Mar 21.

Centre de Recherche en Cancérologie de Marseille, Laboratoire d'Oncologie Moléculaire, UMR1068 Inserm, Institut Paoli-Calmettes, Marseille, France.

View Article and Find Full Text PDF
March 2012